Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

UBS reaffirmed its Buy rating and $105 target for Merck, brushing off investor pessimism about the pharmaceutical giant’s ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

As fired and retired scientists rallied outside in the Atlanta heat, an advisory panel that Robert F. Kennedy Jr. handpicked ...

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new preventive shot against ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...